Atorvastatin treatment and vaccination efficacy

Journal of Clinical Pharmacology

Volumn 47, Issue 8, 2007, Pages 1022-1027

  Packard, René R S ^a   Schlegel, Susanna ^a   Senouf, David ^a   Burger, Fabienne ^a   Sigaud, Philippe ^a   Perneger, Thomas ^a   Siegrist, Claire Anne ^a   Mach, François ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Anti inflammatory effect; Immunomodulation; Statin; Vaccination

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLACEBO; TRIACYLGLYCEROL;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY MASS; CELL DIFFERENTIATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; LIPID BLOOD LEVEL; MALE; NORMAL HUMAN; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SMOKING; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; VACCINATION;

ADULT; ANTIBODY FORMATION; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PYRROLES;

EID: 34447625694     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007302169     Document Type: Article

References (36)

1. Maron DJ, Fazio S., Linton MF Current perspectives on statins. Circulation. 2000 ; 101: 207-213.
2. Plana JC, Jones PH The use of statins in acute coronary syndromes: the mechanisms behind the outcomes. Curr Atheroscler Rep. 2001 ; 3: 355-364.
3. LaRosa JC What do the statins tell us? Am Heart J. 2002 ; 144: S21 - S26.
4. Arnaud C., Braunersreuther V., Mach F. Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med. 2005 ; 15: 202-206.
5. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000 ; 6: 1399-1402.
6. Schonbeck U., Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents ? Circulation. 2004 ; 109: 1118-1126.
7. Steffens S., Mach F. Anti-inflammatory properties of statins. Semin Vasc Med. 2004 ; 4: 417-422.
8. Youssef S., Stuve O., Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002 ; 420: 78-84.
9. Leung BP, Sattar N., Crilly A., et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003 ; 170: 1524-1530.
10. Kobashigawa JA, Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995 ; 333: 621-627.
11. Wenke K., Meiser B., Thiery J., et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation. 1997 ; 96: 1398-1402.
12. McCarey DW, McInnes IB, Madhok R., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 2004 ; 363: 2015-2021.
13. Van Denderen JC, Peters M., Halm VV, et al. Statin therapy might be beneficial for treating patients with ankylosing spondylitis. Ann Rheum Dis. 2006 ; 65: 695-696.
14. Vollmer T., Key L., Durkalski V., et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004 ; 363: 1607-1608.
15. Hohler T., Reuss E., Evers N., et al. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet. 2002 ; 360: 991-995.
16. Machin D. Sample Size Tables for Clinical Studies. 2 nd ed. Oxford, UK: Blackwell Science ; 1997.
17. Andre FE, D'Hondt E., Delem A., Safary A. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine. 1992 ; 10 (suppl 1). S160 - S168.
18. LaRosa JC, He J., Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999 ; 282: 2340-2346.
19. Cheung BM, Lauder IJ, Lau CP, Kumana CR Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol. 2004 ; 57: 640-651.
20. Nissen SE, Nicholls SJ, Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006 ; 295: 1556-1565.
21. Cannon CP, Braunwald E., McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 ; 350: 1495-1504.
22. Pedersen TR, Faergeman O., Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005 ; 294: 2437-2445.
23. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005 ; 45: 89-118.
24. Ray KK, Cannon CP The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol. 2005 ; 46: 1425-1433.
25. Ridker PM, Cannon CP, Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005 ; 352: 20-28.
26. Gurfinkel EP, de la Fuente RL, Mendiz O., Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation. 2002 ; 105: 2143-2147.
27. Grau AJ, Fischer B., Barth C., Ling P., Lichy C., Buggle F. Influenza vaccination is associated with a reduced risk of stroke. Stroke. 2005 ; 36: 1501-1506.
28. Mach F. Statins as immunomodulatory agents. Circulation. 2004 ; 109: 1115-1117.
29. Hakamada-Taguchi R., Uehara Y., Kuribayashi K., et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res. 2003 ; 93: 948-956.
30. Sever PS, Dahlof B., Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003 ; 361: 1149-1158.
31. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004 ; 364: 685-696.
32. Martin-Ventura JL, Blanco-Colio LM, Gomez-Hernandez A., et al. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke. 2005 ; 36: 1796-1800.
33. Rimland D., Guest JL Response to hepatitis A vaccine in HIV patients in the HAART era. AIDS. 2005 ; 19: 1702-1704.
34. Shire NJ, Welge JA, Sherman KE Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical Bayesian meta-analysis. Vaccine. 2006 ; 24: 272-279.
35. Lee PY, Scumpia PO, Byars JA, et al. Short-term atorvastatin treatment enhances specific antibody production following tetanus toxoid vaccination in healthy volunteers. Vaccine. 2006 ; 24: 4035-4040.
36. Connor BA Hepatitis A vaccine in the last-minute traveler. Am J Med. 2005 ; 118 (suppl 10A). 58S - 62S.